Evolution of the Average Target: Lineage Cell Therapeutics, Inc.

Evolution of the Average Target - Lineage Cell Therapeutics, Inc.

Evolution of the Target Price: Lineage Cell Therapeutics, Inc.

Evolution of the Target Price - Lineage Cell Therapeutics, Inc.

Changes in Analyst Recommendations: Lineage Cell Therapeutics, Inc.

6421cee29db.anWJRZCmC7k8yyzJAkq3Vf_6328fEPIa4keOZ2tU7_M.IljhJ6TCRJR9hU3xVSzEBJmrlwlKfrgo1g3nBhFtvroQM94hp8h73XeSeQ~f6e82d3ea2d80fa540e593b704e2253a

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+612.53%
+43.71%
+19.37%
+11.58%
+20.93%
+26.92%
+30.99%
+70.4%
+20.93%
+37.4%
Average +89.47%
Weighted average by Cap. +30.55%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
0.7719USD
Average target price
5.500USD
Spread / Average Target
+612.53%
High Price Target
9.000USD
Spread / Highest target
+1,065.95%
Low Price Target
3.000USD
Spread / Lowest Target
+288.65%

Analyst Consensus Detail

Analyst consensus - Lineage Cell Therapeutics, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Lineage Cell Therapeutics, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Lineage Cell Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. LCTX Stock
  4. Consensus Lineage Cell Therapeutics, Inc.